StockData
AIM ImmunoTech Inc. logo

AIM ImmunoTech Inc. (AIM) stock

AIMNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30
$0.14+0.01 (+3.82%)

Close on Nov 17, 2026Market cap $4.14MP/E –Yield –

AIM ImmunoTech operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

AIM ImmunoTech's operating income for the twelve months ending Jun 30, 2026 was -$11.14M. For fiscal 2025 it was -$11.66M. The highest annual figure on record is -$11.42M in fiscal 2017.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$11.66M–
FY2024Dec 31, 2024-$19.77M–
FY2023Dec 31, 2023-$31.92M–
FY2022Dec 31, 2022-$19.92M–
FY2021Dec 31, 2021-$18.84M–
FY2020Dec 31, 2020-$15.15M–
FY2019Dec 31, 2019-$12.44M–
FY2018Dec 31, 2018-$11.50M–
FY2017Dec 31, 2017-$11.42M–
FY2016Dec 31, 2016-$13.80M–
FY2015Dec 31, 2015-$16.65M–
FY2014Dec 31, 2014-$19.10M–
FY2013Dec 31, 2013-$17.17M–
FY2012Dec 31, 2012-$20.34M–
FY2011Dec 31, 2011-$14.30M–
FY2010Dec 31, 2010-$16.39M–
FY2009Dec 31, 2009-$13.26M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.51M–
Q1 FY2026Mar 31, 2026-$2.23M–
Q4 FY2025Dec 31, 2025-$2.95M–
Q3 FY2025Sep 30, 2025-$2.45M–
Q2 FY2025Jun 30, 2025-$2.65M–
Q1 FY2025Mar 31, 2025-$3.62M–
Q4 FY2024Dec 31, 2024-$5.86M–
Q3 FY2024Sep 30, 2024-$4.49M–
Q2 FY2024Jun 30, 2024-$3.69M–
Q1 FY2024Mar 31, 2024-$5.73M–
Q4 FY2023Dec 31, 2023-$14.00M–
Q3 FY2023Sep 30, 2023-$8.16M–
Q4 FY2022Dec 31, 2022-$5.56M–
Q3 FY2022Sep 30, 2022-$6.52M–
Q2 FY2022Jun 30, 2022-$4.70M–
Q1 FY2022Mar 31, 2022-$3.15M–
Q4 FY2021Dec 31, 2021-$7.45M–
Q3 FY2021Sep 30, 2021-$3.93M–
Q2 FY2021Jun 30, 2021-$3.72M–
Q1 FY2021Mar 31, 2021-$3.75M–
Q4 FY2020Dec 31, 2020-$5.15M–
Q3 FY2020Sep 30, 2020-$3.36M–
Q2 FY2020Jun 30, 2020-$3.34M–
Q1 FY2020Mar 31, 2020-$3.33M–
Q4 FY2019Dec 31, 2019-$3.09M–
Q3 FY2019Sep 30, 2019-$3.21M–
Q2 FY2019Jun 30, 2019-$3.22M–
Q1 FY2019Mar 31, 2019-$2.93M–
Q4 FY2018Dec 31, 2018-$2.66M–
Q3 FY2018Sep 30, 2018-$3.04M–
Q2 FY2018Jun 30, 2018-$3.23M–
Q1 FY2018Mar 31, 2018-$2.57M–
Q4 FY2017Dec 31, 2017-$2.79M–
Q3 FY2017Sep 30, 2017-$2.65M–
Q2 FY2017Jun 30, 2017-$2.73M–
Q1 FY2017Mar 31, 2017-$3.24M–
Q4 FY2016Dec 31, 2016-$4.09M–
Q3 FY2016Sep 30, 2016-$3.23M–
Q2 FY2016Jun 30, 2016-$2.81M–

More AIM ImmunoTech figures

See a number that looks wrong?